 Hepatitis prevention treatment Widespread screening donor blood hepatitis recognition cases post-transfusion hepatitis due agent agents non-A non-B causative agent non-A non-B hepatitis unknown new agent hepatitis virus new cases hepatitis year one-half patients hepatitis chronic liver disease Hepatitis responsible new cases cirrhosis antibody assay commercial use Widespread screening donor blood assay risk transfusion-associated hepatitis patients antiviral therapy alpha interferon chance cure significant palliation